CARB-X
Avails Medical Submits eQUANT System to FDA, Awarded Additional $5.4M from CARB-X
The automated system aims to replace the bacterial subculture step in antimicrobial susceptibility testing for bloodstream infections.
Day Zero Diagnostics Secures Additional $8.2M From CARB-X
The funding will support product development for Day Zero's whole-genome sequencing and machine learning-based diagnostic.
Avails Medical Awarded Additional $1.7M in CARB-X Funding
The funding is intended to accelerate the development of an electric biosensor-based antimicrobial susceptibility test device.
HHS, Wellcome Commit $370M in New Funding for CARB-X
Founded in 2016, CARB-X supports the advancement of therapeutics, vaccines, rapid diagnostics, and devices to treat drug-resistant bacterial infections.
Numerous technologies in development to help with the diagnosis of sepsis have a singular objective ─ detect the condition as quickly as possible.